New liposomal combo aims to control advanced colorectal cancer
NCT ID NCT06540326
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new form of chemotherapy (liposomal irinotecan) combined with standard drugs for people with advanced colorectal cancer that has not responded to first treatment. About 100 adults aged 18-75 will receive this combination to see if it shrinks tumors and delays cancer growth. The goal is to better control the disease, not cure it.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The second affiliated hospital, Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Pronged attack shrink Hard-to-Treat colorectal tumors?
- Can a Two-Drug attack shrink Hard-to-Treat colorectal tumors?
- Can a four-drug cocktail shrink hard-to-treat colorectal cancer?
- Can a Drug-Radiation combo outsmart Treatment-Resistant colorectal cancer?
- Can a cholesterol drug help immunotherapy fight colorectal cancer?
- Could a liver transplant from a living donor help fight colorectal cancer that spread?